Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Arrowhead Pharma (ARWR)

Arrowhead Pharma (ARWR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Arrowhead Pharma 177 E. Colorado Blvd Suite 700 Pasadena CA 91105 USA

www.arrowheadpharma.com Employees: 711 P: 626-304-3400 F: 626-304-3401

Sector:

Medical

Description:

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company which develops novel drugs to treat intractable diseases primarily in the United States. The company's proprietary Dynamic Polyconjugate platform develops drugs based on the RNA interference mechanism which silences disease-causing genes. Its products include ARC-520, ARC-521, ARC-AAT, ARC-F12, ARC-HIF2 and ARC-LPA which are in different clinical trial phase. Arrowhead Pharmaceuticals, Inc., formerly known as Arrowhead Research Corporation, is headquartered in Pasadena, California.

Key Statistics

Overview:

Market Capitalization, $K 9,015,259
Enterprise Value, $K 9,043,589
Shares Outstanding, K 140,032
Float, K 134,991
% Float 96.40%
Short Interest, K 11,150
Short Float 7.96%
Days to Cover 5.68
Short Volume Ratio 0.76
% of Insider Shareholders 3.60%
% of Institutional Shareholders 62.61%

Financials:

Annual Sales, $ 829,450 K
Annual Net Income, $ -1,630 K
Last Quarter Sales, $ 264,030 K
Last Quarter Net Income, $ 30,810 K
EBIT, $ 300,570 K
EBITDA, $ 318,710 K

Growth:

1-Year Return 202.94%
3-Year Return 95.71%
5-Year Return -19.83%
5-Year Revenue Growth 842.66%
5-Year Earnings Growth 98.81%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 0.22 on 02/05/26
Next Earnings Date 05/11/26
Earnings Per Share ttm 1.53
EPS Growth vs. Prev Qtr 222.22%
EPS Growth vs. Prev Year 115.83%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%
Most Recent Split 1-10 on 11/17/11

ARWR Ratios

Ratio
Price/Earnings ttm 41.63
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % 35.64%
Return-on-Assets % 13.61%
Profit Margin % -0.20%
Debt/Equity 0.36
Price/Sales 10.75
Price/Cash Flow 533.42
Price/Book 15.85
Book Value/Share 4.02
Interest Coverage -1.58
60-Month Beta 1.21
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar